2023年3月31日

Genialis宣布它已经筹集了1300万美元。Genialis——计算精度解开复杂的生物医学公司寻找新的方法来解决疾病——宣布筹集到1300万美元的首轮融资将疾病诊断和治疗决策的方式生成。Taiwania资本和Debiopharm创新基金共同资助轮从先前的投资者参与第一明星企业,Redalpine Venture Partners,鼠兔。和其他新投资者包括P5卫生企业和几个天使。Ita Taiwania Lu和Hamzeh消息Debiopharm加入Genialis的董事会。Genialis正在开发先进的病人使用机器学习分类器和高通量组学数据捕捉潜在疾病生物学和预测患者可能会如何应对靶向治疗。和该公司计划使用资金资金扩大自营ResponderID系列平台,构建了全面的临床验证生物标志物模型为几乎所有的癌症患者提供精确的诊断。到目前为止,Genialis ResponderID用于与生物制药合作分析临床试验数据并告知未来试验设计大量临床实验的药物。和Genialis还支持下一代生物标志物的商业化与一些主要诊断公司化验。ResponderID是临床和转化研究机器学习平台——建于从多年的工作经验与几个合作伙伴整个行业和先进的内部研发。 ResponderID brings new biomarkers for drug development and discovery programs along with diagnostic tests. Plus ResponderID can read the status of virtually any NGS-based biomarker, including bespoke and proprietary signatures, from a single assay. The resulting output offers clinical and translational researchers with a comprehensive molecular portrait of patient disease phenotype enabling the most informed decision-making possible. Last year, there were 10 publications and poster presentations at major scientific conferences that featured results generated with ResponderID, including AACR, ESMO, and SITC. Genialis also co-authored a paper in the Journal of Clinical Oncology describing OncXerna’s navicixizumab ph1b trial, including retrospective analysis with the Xerna TME Panel. Now Genialis is growing its teams in the U.S. and Slovenia across the business, operations, life science, and data science functions, and expanding its advisory boards. And the company is also investing in R&D collaborations with several cancer centers, hospital groups, and clinical academic labs. KEY QUOTES: “With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery. We chose to focus initially on biomarkers that improve the efficiency of drug development, that ensure the right patient gets the right medicine, and make an impact on real people’s lives in a shorter period of time.” — Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis “ResponderID, Genialis’ predictive biomarker platform, enables precision medicine by identifying patients that are most likely to respond to treatments. Its use in drug development will optimize study designs and improve chances of clinical trials success, driving much-needed productivity gains for pharma R&D and accelerating the time to market for promising new drugs.” — Hamzeh Abdul-Hadi, Investment Director at Debiopharm Innovation Fund “Genialis is leading the collision of biology and AI. Our approach is biology first, but with a deep commitment to getting the data science right. Thus, we only succeed as a team that understands both worlds. This capital brings together a global syndicate of clinical oncology and deep tech experts and will allow us to grow our in-house capabilities in multiple disciplines.” — Miha Stajdohar, Ph.D., co-founder and CTO of Genialis “Genialis has an impressively clear vision, compelling AI-drug discovery biomarker models, and robust underlying science supporting their platform. We look forward to working closely with the Genialis team to explore and pursue growth opportunities in this burgeoning space.” — Ita Lu, Managing Partner, Taiwania Capital Management Trending on Pulse 2.0